Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nuvectis Pharma Inc (NVCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: NVCT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 18.18% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 192.98M USD | Price to earnings Ratio - | 1Y Target Price 18.33 |
Price to earnings Ratio - | 1Y Target Price 18.33 | ||
Volume (30-day avg) 114412 | Beta -0.12 | 52 Weeks Range 4.44 - 11.80 | Updated Date 04/6/2025 |
52 Weeks Range 4.44 - 11.80 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.11 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -65.65% | Return on Equity (TTM) -173.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 173511206 | Price to Sales(TTM) - |
Enterprise Value 173511206 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.38 | Shares Outstanding 23391500 | Shares Floating 12768250 |
Shares Outstanding 23391500 | Shares Floating 12768250 | ||
Percent Insiders 45.35 | Percent Institutions 6.92 |
Analyst Ratings
Rating 4.33 | Target Price 22 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nuvectis Pharma Inc
Company Overview
History and Background
Nuvectis Pharma, Inc. is a pharmaceutical company focused on developing precision medicines for serious unmet medical needs in oncology. Founded to advance innovative therapies, Nuvectis is dedicated to improving patient outcomes through targeted treatments.
Core Business Areas
- Drug Development: Nuvectis Pharma focuses on developing novel, targeted therapies for various cancers. This includes research, preclinical studies, clinical trials, and regulatory submissions.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives with expertise in drug development and commercialization. The company structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- NXP800: NXP800 is Nuvectis Pharma's lead product candidate, a novel Heat Shock Factor 1 (HSF1) activator designed to stimulate anti-tumor immunity and overcome resistance to existing treatments. As it is still in the development phase, market share and revenue are currently zero. Key competitors focusing on cancer therapies include pharmaceutical giants like Roche (ROG.SW), Novartis (NOVN.SW), and Pfizer (PFE).
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing sector driven by an aging population, advancements in cancer diagnostics, and the development of novel therapies. There is significant unmet need for more effective and targeted treatments.
Positioning
Nuvectis Pharma aims to establish itself as a leader in precision oncology by developing innovative therapies that address specific unmet needs in cancer treatment. Its competitive advantage lies in its focus on novel mechanisms of action and targeted approaches.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is estimated to be hundreds of billions of dollars. Nuvectis Pharma is positioned to capture a portion of this market by developing and commercializing innovative therapies for specific cancer indications.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Focus on precision oncology
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Early-stage development programs
- High regulatory risk
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Accelerated regulatory pathways
- Growing demand for targeted therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Novartis (NOVN.SW)
- Pfizer (PFE)
- Merck (MRK)
Competitive Landscape
Nuvectis Pharma faces intense competition from larger, more established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel approach to cancer therapy and its focus on specific unmet needs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing research and development activities and preclinical milestones.
Future Projections: Future growth depends on the successful clinical development and commercialization of its lead product candidates. Analyst estimates vary widely due to the inherent uncertainty of drug development.
Recent Initiatives: Recent strategic initiatives include advancing its lead product candidate into clinical trials and securing funding for continued research and development.
Summary
Nuvectis Pharma is a development-stage pharmaceutical company with a focus on precision oncology. Its lead product candidate, NXP800, shows promise but faces significant clinical and regulatory risks. The company's success depends on the outcome of clinical trials and its ability to secure funding and partnerships. The limited resources and competitive landscape are risks to consider.
Similar Companies
ARRY
Array Technologies Inc
ARRY
Array Technologies Inc
CRIS
Curis Inc
CRIS
Curis Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Investing in pharmaceutical companies involves significant risks, including the risk of clinical trial failure and regulatory setbacks. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvectis Pharma Inc
Exchange NASDAQ | Headquaters Fort Lee, NJ, United States | ||
IPO Launch date 2022-02-04 | Co-Founder, Chairman, CEO & President Mr. Ron Bentsur M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.nuvectis.com |
Full time employees 13 | Website https://www.nuvectis.com | ||
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.